Questions discussed in this category
If yes, would you go with Zidovudine monotherapy versus combining with interferon-alpha? And what would be the preferred dose and duration?
At the time of count recovery or do you continue it throughout induction and consolidation?
Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?
Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?
1856818549105897526
Papers discussed in this category
The New England journal of medicine, 2007-01-25
J Clin Oncol, 2021 Jul 26
Journal of oncology practice, 2018-09-04
Leukemia & lymphoma, 2022 Mar 15
Hematology. American Society of Hematology. Education Program, 2020 Dec 04